GILUPI CellCollector
home CellCollector about gilupi news contact
german version
Circulating tumor cells
Gilupi method
Practice and clinical validation
Special features



GILUPI CellCollector

The revolutionary in vivo technology of the GILUPI CellCollector® has been published in July 2012 in the International Journal of Oncology.

A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire

Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG, Jansen H, Propping C, Sterzynska K, Dyszkiewicz W, Zabel M, Kiechle M, Reuning U, Schmitt M, Lücke K.

Int J Oncol. 2012 Oct;41(4):1241-50
doi: 10.3892/ijo.2012.1557

Download here


Another scientific publication of the GILUPI CellCollector® technology has been released in December 2016 in the journal “Clinical Cancer Research“:

“Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells”

Gorges TM, Penkalla N, Schalk T, Joosse S, Riethdorf S, Tucholski J, Lucke K, Wikman H, Jackson SM, Brychter N, von Ahsen O, Schumann C, Krahn T, Pantel K.

Clin Cancer Res. 2015 Dec 14. pii: clincanres.1416.2015.

doi: 10.1158/1078-0432.CCR-15-1416


In August 2016 a paper was published describing isolation of circulating tumor cells from blood of prostate cancer patients with GILUPI CellCollector®:

“The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study”

Theil G, Fischer K, Weber E, Medek R, Hoda R, Lücke K, Fornara P.

PLoS One. 2016 Aug 1;11(8):e0158354.

doi: 10.1371/journal.pone.0158354. eCollection 2016.

In October 2016 a published scientific paper demonstrated for the first time circulating tumor cell isolation from blood of neuroendocrine tumor patients with GILUPI CellCollector®:

“A comparison of CellCollector with CellSearch in patients with neuroendocrine tumours”

Endocr Relat Cancer. 2016 Oct;23(10):L29-32.

doi: 10.1530/ERC-16-0201. Epub 2016 Aug 12. No abstract available.

For manuskript please contact us


Since then, the GILUPI CellCollector® technology has been mentioned in other papers on circulating tumor cells:

1 "Biology, detection, and clinical implications of circulating tumor cells"

Joosse SA, Gorges TM, Pantel K.

EMBO Mol Med. 2014 Nov 14. pii: e201303698.


1 "Challenges in circulating tumour cell research"

Alix-Panabières C, Pantel K.

Nat Rev Cancer. 2014 Sep;14(9):623-31.


1 "Molecular analysis of circulating tumour cells —biology and biomarkers."

Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C.

Nat Rev Clin Oncol. 2014 Mar;11(3):129-44.


1 467 Verification of a functionalized structured medical wire for the isolation of circulating tumor cells (CTC) in patients with renal cell carcinoma.

Theil G, Wencker A, Fischer K, Pini G, Lücke K, Fornara P.

J. Urol. 2013 May;189 (4S, Supplement):192. Abstract 467.

Download here

1 Circulating tumor cells as therapy-related biomarkers in cancer patients.

Gorges TM, Pantel K.

Cancer Immunol Immunother. 2013 May;62(5):931-9.
doi: 10.1007/s00262-012-1387-1

1 Circulating tumor cells: liquid biopsy of cancer.

Alix-Panabières C, Pantel K.

Clin Chem. 2013 Jan;59(1):110-8,
doi: 10.1373/clinchem.2012.194258

1 Detection methods of circulating tumor cells.

Pantel K, Alix-Panabières C.

J Thorac Dis. 2012 Oct;4(5):446-7.
doi: 10.3978/j.issn.2072-1439.2012.08.15

1 "Considerations in the development of circulating tumor cell technology for clinical use"

Parkinson et al., J Transl Med. 2012 Jul 2;10:138.
doi: 10.1186/1479-5876-10-138


So far, GILUPI has presented clinical results from GILUPI CellCollector® applications at numerous national and international meetings and exhibitions.
See Previous Events

1st in vivo CTC isolation CE approval worldwide >>
Application possible in all cancer indications, clinical results available for prostate, lung, breast and colorectal cancer >>
Proven safety and functionality >>
70% CTC detection rate >>
CTC detection in all cancer stages >>
GILUPI presentations of clinical results at the following meetings & exhibitions:
DGU (Dresden)
ECCO (Amsterdam)
EAU (Stockholm)
ACTC (Athens)
ISMRC (Paris
ASCO (Chicago)
EBCC (Vienna)
ELCC (Geneva)
DKK (Berlin)
MEDICA (Düsseldorf)